Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-κB Transcriptional Activity
- 1 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (7) , 2178-2190
- https://doi.org/10.1158/1078-0432.ccr-06-1711
Abstract
Purpose: The strategy of intracellular antibodies to neutralize the function of target proteins has been widely developed for cancer research. This study used an intrabody against p65 subunit to prevent nuclear factor κB (NF-κB) transcriptional activity in glioma cells and to inhibit the expression of its target genes involved in the invasion and angiogenesis of human gliomas. Experimental Design: A single-chain fragment of antibody variable region (scFv) against p65 was prepared using phage display technique. We then prepared an anti-p65 intrabody construct (pFv/nu) by cloning the scFv-encoding sequence into the mammalian nuclear-targeting vector, pCMV/myc/nuc. Results: p65 expression in human glioma cells (U251 and] U87) transfected with pFv/nu was significantly decreased. We showed that NF-κB nuclear translocation and its DNA binding activity were blocked via intrabody transfection in electrophoretic mobility shift assays and the inhibition of NF-κB activity in nucleus resulted in the decreasing expression and bioactivity of matrix metalloproteinase-9, urokinase-type plasminogen activator receptor, urokinase-type plasminogen activator, and vascular endothelial growth factor. The intrabody transfected glioma cells showed a markedly lower level of invasion in Matrigel invasion assay. The capillary-like structure formation of endothelial cells was also repressed by coculture with the intrabody transfected glioma cells or exposure to their conditional medium. Intrabody transfection neither induced apoptosis nor altered cell proliferation in U251 and U87 cells as compared with the control vector pCMV/nu. After the injection of pFv/nu-transfected glioma cells, preestablished tumors were almost completely regressed when compared with mock, pCMV/nu, and pGFP/nu. Conclusion: Blocking NF-κB activity via the nuclear intrabody expression might be a potential approach for cancer therapy.Keywords
This publication has 44 references indexed in Scilit:
- RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in VivoJournal of Biological Chemistry, 2005
- Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growthNeuron Glia Biology, 2004
- RNA interferenceNature, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Phosphatidylinositol 3-Kinase and NF-κB Regulate Motility of Invasive MDA-MB-231 Human Breast Cancer Cells by the Secretion of Urokinase-type Plasminogen ActivatorJournal of Biological Chemistry, 2002
- Protein Kinase C Induces Motility of Breast Cancers by Upregulating Secretion of Urokinase-Type Plasminogen Activator through Activation of AP-1 and NF-κBBiochemical and Biophysical Research Communications, 2002
- Intracellular Stability of Anti-caspase-3 Intrabodies Determines Efficacy in Retargeting the AntigenPublished by Elsevier ,2001
- Stability engineering of antibody single-chain Fv fragmentsJournal of Molecular Biology, 2001
- Removal of the conserved disulfide bridges from the scfv fragment of an antibody: effects on folding kinetics and aggregationJournal of Molecular Biology, 1999
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993